The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

Jim Cramer’s 10 Best Stock Picks for Investors Right Now. In this article, we are going to take a look at where Moderna, Inc.

We recently compiled a list of the Jim Cramer’s Top 12 Must-Watch Stocks. In this article, we are going to take a look at where Moderna Inc. (NASDAQ:MRNA) stands against Jim Cramer’s other must-watch ...

ACCESSWIRE • 9 days ago EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.

Moderna shares have dropped by over -41.67% since I last covered them over the summer. See why I continue to rate MRNA stock ...

This follows Moderna's R&D Day where it set a goal for 10 mRNA product approvals by 2027 and outlined plans for several vaccines. The company also estimates product sales between $3 billion and $3 ...

Piper Sandler cut the target to $115 from $157, maintaining an Overweight rating. This follows Moderna's R&D Day where it set a goal for 10 mRNA product approvals by 2027 and outlined plans for ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

It was a busy week for the biotech sector with a lot of important data readouts at the European Society for Medical Oncology ...

Explore Estonia’s biotech scene with 7 pioneering companies across Tallinn, Tartu, and beyond, fueled by top science parks ...